Cabozantinib in children with recurrent diffuse gliomas-Reference-Cited by-同舟云学术

Cabozantinib in children with recurrent diffuse gliomas

Published:2024-06-17 Issue:9 Volume:71 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Papusha Ludmila¹^ORCID,Zaytseva Margarita¹^ORCID,Senchenko Maria¹,Sanakoeva Agunda¹,Panferova Agnesa¹^ORCID,Sharanda Tatiana²,Vilesova Irina¹,Tarakanova Alexandra¹,Salnikova Ekaterina¹,Usman Natalia¹^ORCID,Artemov Anton¹,Karachunskiy Alexander¹,Maschan Alexey¹,Hwang Eugene³⁴^ORCID,Packer Roger J.⁴⁵,Novichkova Galina¹,Druy Alexander¹⁶^ORCID

Affiliation:

1. Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology Moscow Russia

2. Amur Regional Children's Hospital Blagoveshchensk Russia

3. Division of Oncology Children's National Hospital Washington District of Columbia USA

4. Brain Tumor Institute Children's National Hospital Washington District of Columbia USA

5. Center for Neuroscience and Behavioral Medicine Washington District of Columbia USA

6. Research Institute of Medical Cell Technologies Yekaterinburg Russia

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.31149

Reference15 articles.

1. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas

2. Lorlatinib in a Child with ALK-Fusion–Positive High-Grade Glioma

3. Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

4. Cabozantinib for the treatment of solid tumors: a systematic review

5. Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma